Is BDTX or NXTC more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% NextCure N/A -154.62% -100.19%

Do analysts prefer AADI or NXTC?

NextCure has a consensus target price of $19.00, indicating a potential upside of 222.58%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is AADI or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% NextCure N/A -154.62% -100.19%

Which has better earnings & valuation, ENGN or NXTC?

enGene is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is ENGN or NXTC more profitable?

enGene's return on equity of -56.06% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% NextCure N/A -154.62% -100.19%

Which has stronger earnings and valuation, INO or NXTC?

Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inovio Pharmaceuticals N/A N/A -$84.95M -$0.91 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is INO or NXTC more profitable?

NextCure's return on equity of -154.62% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% NextCure N/A -154.62% -100.19%

Is OTLK or NXTC more profitable?

Oncobiologics' return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% NextCure N/A -154.62% -100.19%

NextCure (NXTC) Competitors

$5.89 -0.40 (-6.36%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$5.94 +0.05 (+0.85%)

As of 08:31 AM Eastern

Compare

NXTC vs. BDTX, AADI, ENGN, INO, and OTLK

Should you buy NextCure stock or one of its competitors? NextCure's main competitors and comparable companies include Black Diamond Therapeutics (BDTX), Aadi Bioscience (AADI), enGene (ENGN), Inovio Pharmaceuticals (INO), and Oncobiologics (OTLK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NextCure compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Black Diamond Therapeutics has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market. Comparatively, NextCure has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Black Diamond Therapeutics has higher revenue and earnings than NextCure. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.76	$22.37M	-$0.75	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Black Diamond Therapeutics' return on equity of -32.10% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
NextCure	N/A	-154.62%	-100.19%

Black Diamond Therapeutics presently has a consensus price target of $9.80, suggesting a potential upside of 355.81%. NextCure has a consensus price target of $19.00, suggesting a potential upside of 222.58%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Black Diamond Therapeutics' average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Black Diamond Therapeutics	Neutral
NextCure	Neutral

Summary

Black Diamond Therapeutics beats NextCure on 10 of the 12 factors compared between the two stocks.

How does NextCure compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

NextCure has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
NextCure	N/A	-154.62%	-100.19%

Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, NextCure has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

NextCure has a consensus target price of $19.00, indicating a potential upside of 222.58%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

NextCure has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.66	-$65.76M	-$2.35	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
NextCure	Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

NextCure beats Aadi Bioscience on 7 of the 13 factors compared between the two stocks.

How does NextCure compare to enGene?

enGene (NASDAQ:ENGN) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, NextCure has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

64.2% of enGene shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

enGene's return on equity of -56.06% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
NextCure	N/A	-154.62%	-100.19%

enGene is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

enGene presently has a consensus target price of $11.05, indicating a potential upside of 510.25%. NextCure has a consensus target price of $19.00, indicating a potential upside of 222.58%. Given enGene's higher possible upside, equities research analysts clearly believe enGene is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, enGene had 9 more articles in the media than NextCure. MarketBeat recorded 9 mentions for enGene and 0 mentions for NextCure. enGene's average media sentiment score of 0.29 beat NextCure's score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Overall Sentiment
enGene	Neutral
NextCure	Neutral

Summary

enGene beats NextCure on 8 of the 13 factors compared between the two stocks.

How does NextCure compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Inovio Pharmaceuticals presently has a consensus price target of $3.17, indicating a potential upside of 153.33%. NextCure has a consensus price target of $19.00, indicating a potential upside of 222.58%. Given NextCure's higher probable upside, analysts plainly believe NextCure is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than NextCure. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 0 mentions for NextCure. Inovio Pharmaceuticals' average media sentiment score of 1.00 beat NextCure's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Positive
NextCure	Neutral

Inovio Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, NextCure has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

NextCure's return on equity of -154.62% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
NextCure	N/A	-154.62%	-100.19%

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	N/A	N/A	-$84.95M	-$0.91	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Summary

Inovio Pharmaceuticals beats NextCure on 8 of the 14 factors compared between the two stocks.

How does NextCure compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Oncobiologics has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, NextCure has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Oncobiologics presently has a consensus price target of $4.65, indicating a potential upside of 663.55%. NextCure has a consensus price target of $19.00, indicating a potential upside of 222.58%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncobiologics' return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
NextCure	N/A	-154.62%	-100.19%

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NextCure has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	67.03	-$62.42M	-$0.77	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

In the previous week, Oncobiologics had 11 more articles in the media than NextCure. MarketBeat recorded 11 mentions for Oncobiologics and 0 mentions for NextCure. Oncobiologics' average media sentiment score of 1.05 beat NextCure's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
NextCure	Neutral

Summary

NextCure beats Oncobiologics on 7 of the 13 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.72M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-0.68	11.69	270.59	24.05
Price / Sales	N/A	1,424.26	643.38	104.95
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	0.59	16.99	11.09	6.40
Net Income	-$55.84M	-$22.72M	$3.46B	$347.95M
7 Day Performance	-11.43%	2.48%	1.73%	1.48%
1 Month Performance	38.92%	9.77%	7.34%	5.13%
1 Year Performance	12.84%	57.38%	26.13%	17.00%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	3.8387 of 5 stars	$5.89 -6.4%	$19.00 +222.6%	+14.8%	$22.72M	N/A	N/A	90
BDTX Black Diamond Therapeutics	1.7539 of 5 stars	$2.06 +0.5%	$9.80 +375.7%	-26.4%	$116.06M	$70M	N/A	90	Positive News
AADI Aadi Bioscience	N/A	$4.64 +4.0%	N/A	+171.8%	$114.59M	$25.07M	N/A	40
ENGN enGene	2.8719 of 5 stars	$1.72 +1.2%	$11.05 +542.2%	-58.1%	$113.87M	N/A	N/A	31
INO Inovio Pharmaceuticals	3.1396 of 5 stars	$1.20 +4.3%	$3.17 +163.9%	-36.2%	$112.70M	$60K	N/A	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. BDTX, AADI, ENGN, INO, and OTLK

How does NextCure compare to Black Diamond Therapeutics?

Summary

How does NextCure compare to Aadi Bioscience?

Summary

How does NextCure compare to enGene?

Summary

How does NextCure compare to Inovio Pharmaceuticals?

Summary

How does NextCure compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. BDTX, AADI, ENGN, INO, and OTLK

How does NextCure compare to Black Diamond Therapeutics?

Which has more volatility & risk, BDTX or NXTC?

Which has higher valuation & earnings, BDTX or NXTC?

Do institutionals and insiders hold more shares of BDTX or NXTC?

Is BDTX or NXTC more profitable?

Do analysts rate BDTX or NXTC?

Does the media favor BDTX or NXTC?

Summary

How does NextCure compare to Aadi Bioscience?

Is AADI or NXTC more profitable?

Which has more risk & volatility, AADI or NXTC?

Do analysts prefer AADI or NXTC?

Which has stronger earnings & valuation, AADI or NXTC?

Does the media refer more to AADI or NXTC?

Do insiders and institutionals believe in AADI or NXTC?

Summary

How does NextCure compare to enGene?

Which has more risk & volatility, ENGN or NXTC?

Do institutionals & insiders have more ownership in ENGN or NXTC?

Is ENGN or NXTC more profitable?

Which has better earnings & valuation, ENGN or NXTC?

Do analysts prefer ENGN or NXTC?

Does the media favor ENGN or NXTC?

Summary

How does NextCure compare to Inovio Pharmaceuticals?

Do analysts rate INO or NXTC?

Does the media refer more to INO or NXTC?

Which has more volatility and risk, INO or NXTC?

Is INO or NXTC more profitable?

Do insiders and institutionals have more ownership in INO or NXTC?

Which has stronger earnings and valuation, INO or NXTC?

Summary

How does NextCure compare to Oncobiologics?

Which has more risk & volatility, OTLK or NXTC?

Do analysts recommend OTLK or NXTC?

Is OTLK or NXTC more profitable?

Do institutionals and insiders believe in OTLK or NXTC?

Which has better earnings and valuation, OTLK or NXTC?

Does the media favor OTLK or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools